ECSP034439A - Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c - Google Patents
Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis cInfo
- Publication number
- ECSP034439A ECSP034439A EC2003004439A ECSP034439A ECSP034439A EC SP034439 A ECSP034439 A EC SP034439A EC 2003004439 A EC2003004439 A EC 2003004439A EC SP034439 A ECSP034439 A EC SP034439A EC SP034439 A ECSP034439 A EC SP034439A
- Authority
- EC
- Ecuador
- Prior art keywords
- hepatitis
- virus
- inhibitors
- new peptides
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/50—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
- C07C205/51—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención describe nuevos compuestos peptidicos que tienen actividad inhibidora de la proteasa HCV así como también métodos para preparar dichos compuestos. En otra realización, la invención describe composiciones farmacéuticas que comprenden dichos compuestos así como también los métodos de uso de los mismos para tratar desórdenes que están asociados con la proteasa HCV.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22010700P | 2000-07-21 | 2000-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP034439A true ECSP034439A (es) | 2003-03-10 |
Family
ID=22822091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2003004439A ECSP034439A (es) | 2000-07-21 | 2003-01-20 | Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c |
Country Status (22)
Country | Link |
---|---|
US (2) | US7169760B2 (es) |
EP (1) | EP1303487A4 (es) |
JP (2) | JP4452441B2 (es) |
KR (1) | KR20030081297A (es) |
CN (1) | CN1446201A (es) |
AR (1) | AR030249A1 (es) |
AU (1) | AU8063701A (es) |
BR (1) | BR0112666A (es) |
CA (1) | CA2410682A1 (es) |
CZ (1) | CZ2003195A3 (es) |
EC (1) | ECSP034439A (es) |
HU (1) | HUP0303358A3 (es) |
IL (1) | IL153669A0 (es) |
MX (1) | MXPA03000626A (es) |
NO (1) | NO20030271L (es) |
NZ (1) | NZ523781A (es) |
PE (1) | PE20020266A1 (es) |
PL (1) | PL365695A1 (es) |
RU (1) | RU2003105221A (es) |
SK (1) | SK742003A3 (es) |
WO (1) | WO2002008187A1 (es) |
ZA (1) | ZA200210311B (es) |
Families Citing this family (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL194025B1 (pl) | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
DE60138567D1 (de) * | 2000-12-12 | 2009-06-10 | Schering Corp | Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus |
WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
CA2441378A1 (en) | 2001-03-22 | 2002-10-03 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
EP1379637A4 (en) | 2001-03-27 | 2005-04-06 | Dendreon Corp | TRANSMEMBRANE SERINE PROTEASE 9 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED, AND METHODS FORMING THEREOF |
JP2005506832A (ja) | 2001-05-14 | 2005-03-10 | デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー | トランスメンブランセリンプロテアーゼ10をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法 |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
KR20110028665A (ko) | 2002-04-11 | 2011-03-21 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 c형 간염 바이러스 ns3-ns4 프로테아제의 억제제 |
CN103275159A (zh) | 2002-06-28 | 2013-09-04 | 埃迪尼克斯医药公司 | 用于治疗黄病毒感染的修饰的2’和3’-核苷前药 |
AU2003304040A1 (en) | 2002-10-08 | 2004-11-04 | Viropharma Incorporated | Anthranilic acid derivatives useful in treating infection with hepatitis c virus |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
BRPI0410456B8 (pt) | 2003-05-21 | 2021-05-25 | Boehringer Ingelheim Int | compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação |
CN100503628C (zh) | 2003-05-30 | 2009-06-24 | 法莫赛特股份有限公司 | 修饰的氟化核苷类似物 |
KR20060084845A (ko) | 2003-07-25 | 2006-07-25 | 이데닉스 (케이만) 리미티드 | C형 간염을 포함하는 플라비비리다에를 치료하기 위한퓨린 뉴클레오시드 유사체 |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7449447B2 (en) | 2003-08-26 | 2008-11-11 | Schering Corporation | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus |
TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
ATE500264T1 (de) | 2003-09-22 | 2011-03-15 | Boehringer Ingelheim Int | Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus |
US7592419B2 (en) * | 2003-09-26 | 2009-09-22 | Schering Corporation | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease |
EP2361925A1 (en) | 2003-10-10 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
WO2005043118A2 (en) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
JP4682155B2 (ja) | 2004-01-21 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウイルスに対して活性な大環状ペプチド |
US7683033B2 (en) | 2004-02-04 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
JP4143669B2 (ja) | 2004-02-24 | 2008-09-03 | 日本たばこ産業株式会社 | 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
RU2006134002A (ru) | 2004-02-27 | 2008-04-10 | Шеринг Корпорейшн (US) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с |
US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
WO2005087730A1 (en) | 2004-02-27 | 2005-09-22 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
TW200602037A (en) | 2004-02-27 | 2006-01-16 | Schering Corp | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease |
WO2005085197A1 (en) * | 2004-02-27 | 2005-09-15 | Schering Corporation | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
CA2557322A1 (en) | 2004-02-27 | 2005-09-15 | Schering Corporation | Inhibitors of hepatitis c virus ns3 protease |
US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
AU2005222060A1 (en) | 2004-02-27 | 2005-09-22 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
ES2328596T3 (es) | 2004-05-20 | 2009-11-16 | Schering Corporation | Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c. |
ES2366478T3 (es) | 2004-07-20 | 2011-10-20 | Boehringer Ingelheim International Gmbh | Análogos peptídicos inhibidores de la hepatitis c. |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
WO2006021409A1 (en) * | 2004-08-25 | 2006-03-02 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-keto carbonyl calpain inhibitors |
CN101068828A (zh) | 2004-08-27 | 2007-11-07 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物 |
EP3109244B1 (en) | 2004-09-14 | 2019-03-06 | Gilead Pharmasset LLC | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
AR055198A1 (es) * | 2005-06-02 | 2007-08-08 | Schering Corp | Formulaciones farmaceuticas y metodos de tratamiento que las utilizan |
EP1891089B1 (en) | 2005-06-02 | 2014-11-05 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
BRPI0613142A2 (pt) | 2005-06-17 | 2010-12-21 | Novartis Ag | uso de sangliferina em hcv |
US20110104109A1 (en) * | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
EP2256113A1 (en) | 2005-08-02 | 2010-12-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
KR20130038947A (ko) | 2005-08-19 | 2013-04-18 | 버텍스 파마슈티칼스 인코포레이티드 | 방법 및 중간체 |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US7964624B1 (en) * | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
JP5409008B2 (ja) | 2005-11-11 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルス改変体 |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
KR20080112303A (ko) | 2006-03-16 | 2008-12-24 | 버텍스 파마슈티칼스 인코포레이티드 | 중수소화 c형 간염 프로테아제 억제제 |
EP1998759A2 (en) * | 2006-03-23 | 2008-12-10 | Schering Corporation | Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
AU2007238253A1 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | HCV inhibitors |
AU2007249668B2 (en) | 2006-04-11 | 2011-04-07 | Novartis Ag | HCV/HIV inhibitors and their uses |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
JP2009542620A (ja) * | 2006-06-30 | 2009-12-03 | ピラマル・ライフ・サイエンシーズ・リミテッド | 口腔疾患治療用の薬草組成物 |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
MX2009000882A (es) | 2006-08-17 | 2009-02-04 | Boehringer Ingelheim Int | Inhibidores de la polimerasa virica. |
US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
JP5079818B2 (ja) | 2006-12-22 | 2012-11-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvおよび関連するウイルス疾患の治療または予防のための4,5−環インドール誘導体 |
CN101611025A (zh) | 2006-12-22 | 2009-12-23 | 先灵公司 | 5,6-环化的吲哚衍生物及其使用方法 |
US8546420B2 (en) * | 2006-12-22 | 2013-10-01 | Merck Sharp & Dohme Corp. | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections |
ATE542815T1 (de) | 2007-02-27 | 2012-02-15 | Vertex Pharma | Kokristalle und pharmazeutische zusammensetzungen damit |
CN101903392A (zh) * | 2007-02-27 | 2010-12-01 | 弗特克斯药品有限公司 | 丝氨酸蛋白酶的抑制剂 |
WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
PL2144604T3 (pl) | 2007-02-28 | 2012-02-29 | Conatus Pharmaceuticals Inc | Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830 |
AU2008230460A1 (en) * | 2007-03-23 | 2008-10-02 | National University Corporation Chiba University | Preventive or therapeutic composition for liver disease |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8258116B2 (en) | 2007-05-04 | 2012-09-04 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
JP2010535156A (ja) | 2007-08-03 | 2010-11-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼ阻害剤 |
CA2697375A1 (en) * | 2007-08-29 | 2009-03-12 | Schering Corporation | 2, 3-substituted indole derivatives for treating viral infections |
EP2408761B1 (en) | 2007-08-29 | 2014-01-01 | Merck Sharp & Dohme Corp. | Substituted indole derivatives and methods of use thereof |
US8404845B2 (en) * | 2007-08-29 | 2013-03-26 | Merck Sharp & Dohme Corp. | 2,3-substituted azaindole derivatives for treating viral infections |
CN101835774B (zh) | 2007-08-30 | 2014-09-17 | 弗特克斯药品有限公司 | 共晶体和包含该共晶体的药物组合物 |
CA2705586A1 (en) * | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-heterocyclic substituted indole derivatives and methods of use thereof |
CN102317285A (zh) * | 2007-11-16 | 2012-01-11 | 先灵公司 | 3-氨基磺酰基取代的吲哚衍生物及其使用方法 |
EA201000948A1 (ru) | 2007-12-19 | 2011-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы вирусной полимеразы |
AU2009210789B2 (en) | 2008-02-04 | 2014-01-30 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
AR072088A1 (es) * | 2008-06-13 | 2010-08-04 | Schering Corp | Derivados de indol triciclicos y sus metodos de uso |
TW201004632A (en) | 2008-07-02 | 2010-02-01 | Idenix Pharmaceuticals Inc | Compounds and pharmaceutical compositions for the treatment of viral infections |
JP5619743B2 (ja) | 2008-08-20 | 2014-11-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用 |
CA2734488A1 (en) | 2008-08-20 | 2010-02-25 | Southern Research Institute | Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
AU2009282571B2 (en) | 2008-08-20 | 2014-12-11 | Merck Sharp & Dohme Corp. | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
TWI409265B (zh) | 2008-08-20 | 2013-09-21 | Merck Sharp & Dohme | 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途 |
NZ593649A (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Nucleoside analogs |
PT2376088T (pt) | 2008-12-23 | 2017-05-02 | Gilead Pharmasset Llc | Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída |
BRPI0923815A2 (pt) | 2008-12-23 | 2015-07-14 | Pharmasset Inc | Síntese de nucleosídeos de purina |
CN102271699A (zh) | 2009-01-07 | 2011-12-07 | 西尼克斯公司 | 用于治疗hcv和hiv感染的环孢菌素衍生物 |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
US8193372B2 (en) | 2009-03-04 | 2012-06-05 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole HCV polymerase inhibitors |
WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
LT2421527T (lt) * | 2009-04-25 | 2018-09-10 | F. Hoffmann-La Roche Ag | Farmakokinetinių savybių pagerinimo būdai |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
EP2435424B1 (en) | 2009-05-29 | 2015-01-21 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
EP2461811B1 (en) | 2009-08-05 | 2016-04-20 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
CA2782024A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
BR112012014899A2 (pt) | 2009-12-18 | 2017-03-14 | Idenix Pharmaceuticals Inc | composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus |
EP2516449A1 (en) | 2009-12-22 | 2012-10-31 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
GB201001070D0 (en) | 2010-01-22 | 2010-03-10 | St George's Hospital Medical School | Theraputic compounds and their use |
EP2536410B1 (en) | 2010-02-18 | 2015-09-23 | Merck Sharp & Dohme Corp. | Substituted pyrimidine derivatives and their use in treating viral infections |
AR080676A1 (es) | 2010-03-09 | 2012-05-02 | Schering Corp | Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales |
DK2552930T3 (en) | 2010-03-31 | 2015-12-07 | Gilead Pharmasset Llc | Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-DIHYDROPYRIMIDIN- 1- (2 H) -yl) - 4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate |
US8680071B2 (en) | 2010-04-01 | 2014-03-25 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
AU2011286276A1 (en) | 2010-07-26 | 2013-01-24 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
EP2621279B1 (en) | 2010-09-29 | 2018-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
WO2012048235A1 (en) | 2010-10-08 | 2012-04-12 | Novartis Ag | Vitamin e formulations of sulfamide ns3 inhibitors |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
CA2843324A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
SG194485A1 (en) | 2011-04-13 | 2013-12-30 | Merck Sharp & Dohme | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
EP2755985B1 (en) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013039920A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
EP2755981A4 (en) | 2011-09-14 | 2015-03-25 | Merck Sharp & Dohme | HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES |
TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物 |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
WO2013082476A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
KR20150013825A (ko) | 2012-05-22 | 2015-02-05 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 간 질환을 위한 d-아미노산 화합물 |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
EA030189B8 (ru) | 2012-10-08 | 2018-10-31 | Иденикс Фармасьютикалз Ллс | Аналоги 2'-хлоронуклеозидов для инфекции вгс |
EP2909223B1 (en) | 2012-10-19 | 2017-03-22 | Idenix Pharmaceuticals LLC | Dinucleotide compounds for hcv infection |
EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
EP2970358B1 (en) | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-deoxy nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
PT3038601T (pt) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
WO2015065817A1 (en) | 2013-10-30 | 2015-05-07 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
WO2015066370A1 (en) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
US20170198005A1 (en) | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
EP3083654A1 (en) | 2013-12-18 | 2016-10-26 | Idenix Pharmaceuticals LLC | 4'-or nucleosides for the treatment of hcv |
WO2015134780A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
EP3114122A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
EP3472149B1 (en) | 2016-06-21 | 2023-08-30 | Orion Ophthalmology LLC | Heterocyclic prolinamide derivatives |
WO2022265577A2 (en) * | 2021-06-15 | 2022-12-22 | Agency For Science, Technology And Research | Coronavirus enzyme modulators, methods of synthesis and uses thereof |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496927A (en) | 1985-02-04 | 1996-03-05 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
IL77748A (en) | 1985-02-04 | 1991-11-21 | Merrell Dow Pharma | Amino acid and peptide derivatives as peptidase inhibitors |
DE318216T1 (de) | 1987-11-18 | 1990-06-13 | Chiron Corp., Emeryville, Calif. | Nanbv-diagnostika und vakzine. |
ZA897515B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
WO1990012805A1 (en) | 1989-04-15 | 1990-11-01 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Postostatin and related compound thereof, or their salts |
US5359138A (en) | 1989-04-15 | 1994-10-25 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
US5371017A (en) * | 1990-04-04 | 1994-12-06 | Chiron Corporation | Hepatitis C virus protease |
JP2804817B2 (ja) | 1990-04-13 | 1998-09-30 | 財団法人微生物化学研究会 | 3―アミノ―2―オキソ脂肪酸誘導体の製造法 |
JPH04149166A (ja) | 1990-10-12 | 1992-05-22 | Nippon Kayaku Co Ltd | 新規ケト酸アミド誘導体 |
WO1992011850A2 (en) | 1990-12-28 | 1992-07-23 | Cortex Pharmaceuticals, Inc. | Use of calpain inhibitors in the inhibition and treatment of neurodegeneration |
WO1993015193A1 (en) | 1992-01-31 | 1993-08-05 | Abbott Laboratories | Mammalian expression systems for hcv proteins |
AU4544993A (en) | 1992-06-24 | 1994-01-24 | Cortex Pharmaceuticals, Inc. | Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity |
US5514694A (en) | 1992-09-21 | 1996-05-07 | Georgia Tech Research Corp | Peptidyl ketoamides |
US5414018A (en) | 1993-09-24 | 1995-05-09 | G. D. Searle & Co. | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension |
US5843450A (en) | 1994-02-14 | 1998-12-01 | Abbott Laboratories | Hepatitis GB Virus synthetic peptides and uses thereof |
IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
US5843752A (en) | 1995-05-12 | 1998-12-01 | Schering Corporation | Soluble active hepatitis C virus protease |
US5919765A (en) * | 1995-06-07 | 1999-07-06 | Cor Therapeutics, Inc. | Inhibitors of factor XA |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
US5763576A (en) | 1995-10-06 | 1998-06-09 | Georgia Tech Research Corp. | Tetrapeptide α-ketoamides |
IL120310A (en) | 1996-03-01 | 2002-02-10 | Akzo Nobel Nv | Serine protease inhibitors and pharmaceuticals containing them |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
IT1285158B1 (it) | 1996-09-17 | 1998-06-03 | Angeletti P Ist Richerche Bio | Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il |
CN1238002A (zh) * | 1996-09-24 | 1999-12-08 | 普罗格特-甘布尔公司 | 含有蛋白水解酶、肽醛和硼酸源的液体洗涤剂 |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
PL194025B1 (pl) | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
WO1998029435A1 (en) | 1996-12-27 | 1998-07-09 | Boehringer Ingelheim (Canada) Ltd. | Peptidomimetic inhibitors of the human cytomegalovirus protease |
WO1998037180A2 (en) | 1997-02-22 | 1998-08-27 | Abbott Laboratories | Hcv fusion protease and polynucleotide encoding same |
WO1999007734A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
EP1003775B1 (en) | 1997-08-11 | 2005-03-16 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
GB9809664D0 (en) | 1998-05-06 | 1998-07-01 | Hoffmann La Roche | a-Ketoamide derivatives |
WO1999064422A1 (en) | 1998-06-09 | 1999-12-16 | Neurogen Corporation | Pyrido[2,3-b]indolizine derivatives and aza analogues thereof; crf1 specific ligands |
GB9812523D0 (en) * | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6576613B1 (en) | 1998-07-24 | 2003-06-10 | Corvas International, Inc. | Title inhibitors of urokinase |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
JP2000256396A (ja) | 1999-03-03 | 2000-09-19 | Dainippon Pharmaceut Co Ltd | 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤 |
JP2003526634A (ja) * | 1999-12-03 | 2003-09-09 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | C型肝炎ウイルスNS3プロテアーゼのα−ケトアミド阻害剤 |
IL152022A0 (en) | 2000-04-03 | 2003-04-10 | Vertex Pharma | Compounds useful as protease inhibitors and pharmaceutical compositions containing the same |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
-
2001
- 2001-07-19 CA CA002410682A patent/CA2410682A1/en not_active Abandoned
- 2001-07-19 MX MXPA03000626A patent/MXPA03000626A/es unknown
- 2001-07-19 BR BR0112666-0A patent/BR0112666A/pt not_active IP Right Cessation
- 2001-07-19 PE PE2001000733A patent/PE20020266A1/es not_active Application Discontinuation
- 2001-07-19 AU AU8063701A patent/AU8063701A/xx not_active Withdrawn
- 2001-07-19 EP EP01959041A patent/EP1303487A4/en not_active Withdrawn
- 2001-07-19 SK SK74-2003A patent/SK742003A3/sk unknown
- 2001-07-19 NZ NZ523781A patent/NZ523781A/en unknown
- 2001-07-19 IL IL15366901A patent/IL153669A0/xx unknown
- 2001-07-19 CZ CZ2003195A patent/CZ2003195A3/cs unknown
- 2001-07-19 CN CN01813921A patent/CN1446201A/zh active Pending
- 2001-07-19 HU HU0303358A patent/HUP0303358A3/hu unknown
- 2001-07-19 JP JP2002514094A patent/JP4452441B2/ja not_active Expired - Fee Related
- 2001-07-19 RU RU2003105221/04A patent/RU2003105221A/ru not_active Application Discontinuation
- 2001-07-19 PL PL01365695A patent/PL365695A1/xx not_active Application Discontinuation
- 2001-07-19 WO PCT/US2001/022813 patent/WO2002008187A1/en active IP Right Grant
- 2001-07-19 KR KR10-2003-7000861A patent/KR20030081297A/ko not_active Application Discontinuation
- 2001-07-19 US US09/909,012 patent/US7169760B2/en not_active Expired - Lifetime
- 2001-07-20 AR ARP010103451A patent/AR030249A1/es unknown
-
2002
- 2002-12-19 ZA ZA200210311A patent/ZA200210311B/en unknown
-
2003
- 2003-01-20 NO NO20030271A patent/NO20030271L/no not_active Application Discontinuation
- 2003-01-20 EC EC2003004439A patent/ECSP034439A/es unknown
-
2005
- 2005-03-24 US US11/089,192 patent/US7595299B2/en not_active Expired - Lifetime
-
2009
- 2009-08-06 JP JP2009183355A patent/JP2009292832A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
IL153669A0 (en) | 2003-07-06 |
US7169760B2 (en) | 2007-01-30 |
MXPA03000626A (es) | 2004-07-30 |
AU8063701A (en) | 2002-02-05 |
JP4452441B2 (ja) | 2010-04-21 |
US20020160962A1 (en) | 2002-10-31 |
CN1446201A (zh) | 2003-10-01 |
JP2009292832A (ja) | 2009-12-17 |
PE20020266A1 (es) | 2002-05-11 |
NO20030271D0 (no) | 2003-01-20 |
KR20030081297A (ko) | 2003-10-17 |
CZ2003195A3 (cs) | 2003-04-16 |
JP2004513881A (ja) | 2004-05-13 |
PL365695A1 (en) | 2005-01-10 |
US20050176648A1 (en) | 2005-08-11 |
EP1303487A1 (en) | 2003-04-23 |
HUP0303358A2 (hu) | 2004-01-28 |
HUP0303358A3 (en) | 2005-10-28 |
CA2410682A1 (en) | 2002-01-31 |
AR030249A1 (es) | 2003-08-13 |
US7595299B2 (en) | 2009-09-29 |
WO2002008187A1 (en) | 2002-01-31 |
NZ523781A (en) | 2004-10-29 |
ZA200210311B (en) | 2004-03-19 |
NO20030271L (no) | 2003-03-18 |
EP1303487A4 (en) | 2005-11-23 |
RU2003105221A (ru) | 2004-09-20 |
SK742003A3 (en) | 2003-06-03 |
BR0112666A (pt) | 2003-06-10 |
WO2002008187A9 (en) | 2003-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP034439A (es) | Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c | |
AR029851A1 (es) | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c | |
ECSP034438A (es) | Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c | |
ECSP066794A (es) | Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
ECSP045191A (es) | "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c" | |
ECSP066626A (es) | Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
ECSP066795A (es) | Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
ECSP066791A (es) | Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
ECSP066792A (es) | Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
ECSP014009A (es) | Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas | |
ECSP099685A (es) | Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
TWI265927B (en) | Novel compounds as NS3-serine protease inhibitors of hepatitis C virus | |
BR112018011711A2 (pt) | peptídeos de direcionamento para direcionar virus adeno-associados (aav) | |
BR0110104A (pt) | Inibidores de ns-3 serina rotease macrocìclica do vìrus da hepatite c compreendendo porções de alquil e aril alanina p2 | |
WO2002008251A3 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
AR030591A1 (es) | Inhibidores de proteasa peptidomimetica | |
EA200800178A1 (ru) | Ингибиторы вируса гепатита с (hcv) | |
ES2240446T3 (es) | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. | |
MX2009010205A (es) | Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c. | |
DOP2021000028A (es) | Formulaciones de dendrímeros | |
DK1668027T3 (da) | Cykliske peptider, der virker som urotensin-II antagonister | |
ATE487729T1 (de) | Als antivirale mittel geeignete azacytosinderivate |